14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
TYL vs WST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) captures the overall head-to-head institutional edge over Tyler Technologies, Inc. (TYL) on higher Unified Composite conviction (39.8/100 SELL vs. 40.4/100 SELL) after splitting the core matrix 7–2 (led by Growth & Scale, Profitability & Quality), while TYL wins 4–2 across the 6-pillar growth and valuation breakdown. TYL trades at $414.03 (27.4x Forward P/E, 15.7% operating margin) versus WST at $413.28 (40.2x Forward P/E, 22.9% operating margin).
Composite vs. Pillar Nuance: While TYL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (22.9% vs. 15.7% operating margin) and revenue trajectory (+8.7% vs. +8.7% YoY).
Defensive Composite Rating Caution: Although WST compares more favorably head-to-head, both TYL (40.4/100 SELL) and WST (39.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Software - Application value chain with $16.9B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment32.0% of Rev ($794M)
90D Engineering Disclosures0 Published
WST Moat ProfileScale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $29.0B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment14.7% of Rev ($499M)
90D Engineering Disclosures0 Published
Investor FAQ TYL vs WST Key Questions & Quantitative Answers
As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) captures the overall head-to-head institutional edge over Tyler Technologies, Inc. (TYL) on higher Unified Composite conviction (39.8/100 SELL vs. 40.4/100 SELL) after splitting the core matrix 7–2 (led by Growth & Scale, Profitability & Quality), while TYL wins 4–2 across the 6-pillar growth and valuation breakdown. TYL trades at $414.03 (27.4x Forward P/E, 15.7% operating margin) versus WST at $413.28 (40.2x Forward P/E, 22.9% operating margin). Composite vs. Pillar Nuance: While TYL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (22.9% vs. 15.7% operating margin) and revenue trajectory (+8.7% vs. +8.7% YoY). Defensive Composite Rating Caution: Although WST compares more favorably head-to-head, both TYL (40.4/100 SELL) and WST (39.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
WST leads the Growth & Scale pillar: TYL posts +8.7% YoY revenue growth and +20.7% YoY earnings growth on $2.48B TTM revenue (47.7% gross margin, 15.7% operating margin), compared with WST at +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), TYL cumulative revenue shifted +147.9% while WST shifted +78.5%. In operating R&D and SG&A reinvestment, TYL deploys 32.0% of Rev ($794M) (0 90-day corporate R&D disclosures) versus 14.7% of Rev ($499M) (0 disclosures) for WST.
TYL screens cheaper on headline valuation multiples. TYL trades at 27.4x Forward P/E, 52.9x Trailing P/E, 1.54x PEG, and 7.1x EV/Revenue (29.6% FCF margin), whereas WST trades at 40.2x Forward P/E, 46.7x Trailing P/E, 3.03x PEG, and 8.5x EV/Revenue (13.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TYL (10.5% ROE) versus WST (21.2% ROE) capital efficiency.
In options market volatility and institutional positioning, TYL carries 39.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (-0.39β · 42% Vol realized risk). By comparison, WST carries 26.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.